A systematic review and meta-analysis of 12 clinical trials, that looked at the immune-associated endocrine disorders linked to PD-1 inhibitors therapy for solid tumors, suggested that pembrolizumab could raise the risk of all-grade endocrine disorders (9.85 folds), hypothyroidism (7.73 folds), and hyperthyroidism (five folds) [7]. Here, PDCD1 is linked to hyperthyroidism.